NewsRx

Search our medical news database

Non-Small Cell Lung Cancer

Liposomal Vaccine is Immunotherapeutic at Higher Dose

Published in Vaccine Weekly, November 15th, 2000

A liposomal vaccine targeting the MUC1 peptide stimulated immune responses in non-small cell lung cancer (NSCLC) patients enrolled in a Phase I study.

"A liposomal formulation of a 25-amino acid MUC1 lipopetide vaccine was tested in a Phase I study of 16 patients with either stage IIIB or IV NSCLC," stated Martin Clive Palmer and colleagues from the Cross Cancer Institute and Biomira, Inc., Edmonton, Canada.

Palmer et al. presented data from their study at the 36th Annual Meeting of the American Society of Clinical Oncology, held in New Orleans, Louisiana. The title of their presentation was "Phase I study of BLP25 (MUC1 peptide) liposomal vaccine...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook